GLP-1 Receptor Agonists show low, inconsistent risk of Non-Arteritic Anterior Ischemic Optic Neuropathy

The widespread use of Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) for type 2 diabetes and obesity has raised questions about potential adverse effects. Recently, a possible association between GLP-1 RAs and non-arteritic anterior ischemic optic neuropathy (NAION), a sudden vision loss condition due to impaired blood flow to the optic nerve, has emerged from observational studies. This consensus statement addresses the clinical uncertainty surrounding this potential link, providing guidance for patients and healthcare providers.

The North American Neuro-Ophthalmology Society and the American Academy of Ophthalmology convened to provide expert opinion and clinical guidance on the potential association between GLP-1 RAs and NAION. This involved a comprehensive review of currently available evidence, which primarily consisted of retrospective observational studies. The expert panel critically evaluated studies that relied on analyses of electronic health records and administrative claims data, acknowledging their inherent limitations and potential biases in assessing causality and risk magnitude.

The consensus statement concluded that while some retrospective observational studies report a small possible increased risk of NAION in patients taking GLP-1 RAs, including semaglutide, other studies report no correlation. The overall magnitude of the potential risk of NAION remains low. The evidence base was characterized by limitations, particularly the reliance on administrative claims data, which can introduce confounding factors and misclassification bias. The expert panel emphasized the inconsistency across studies regarding a definitive association. The consensus highlights that the current evidence does not establish a strong, consistent causal link between GLP-1 RAs and NAION, and any potential increased risk is considered minor.